Moxifloxacin modulates inflammation during murine pneumonia

Respiratory Research

Volumn 15, Issue 1, 2014, Pages

  Beisswenger, Christoph ^a   Honecker, Anja ^a   Kamyschnikow, Andreas ^a   Bischoff, Markus ^a   Tschernig, Thomas ^a   Bals, Robert ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Infection; Inflammation; Moxifloxacin; Pneumonia

Indexed keywords

ANTIINFECTIVE AGENT; MOXIFLOXACIN; QUINOLONE DERIVATIVE; INTERLEUKIN 17; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; C57BL MOUSE; CELLULAR IMMUNITY; DRUG EFFECTS; IMMUNOLOGY; INFLAMMATION; LUNG; MOUSE; PATHOLOGY; PNEUMONIA, BACTERIAL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIAL PNEUMONIA; BACTERIAL VIABILITY; CELL COUNT; CONTROLLED STUDY; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; INOCULATION; LUNG ALVEOLUS CELL; LUNG LAVAGE; NEUTROPHIL; NONHUMAN; PLASMA; PROTEIN EXPRESSION; PSEUDOMONAS AERUGINOSA; SHORT COURSE THERAPY; STREPTOCOCCUS PNEUMONIAE;

ANIMALS; ANTI-BACTERIAL AGENTS; FLUOROQUINOLONES; IMMUNITY, CELLULAR; INFLAMMATION; LUNG; MICE; MICE, INBRED C57BL; PNEUMONIA, BACTERIAL;

EID: 84904272657     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-15-82     Document Type: Article

References (30)

1. Sethi S. Infection as a comorbidity of COPD. Eur Respir J 2010, 35:1209-1215. 10.1183/09031936.00081409, 20513910.
2. Witzenrath MB, Gutbier AC, Hocke B, Schmeck S, Hippenstiel K, Berger TJ, Mitchell JR, DeLos Toyos S, Rosseau N, Suttorp H, Schutte. Role of pneumolysin for the development of acute lung injury in pneumococcal pneumonia. Crit Care Med 2006, 34:1947-1954. 10.1097/01.CCM.0000220496.48295.A9, 16715037.
3. Matthay MA, Ware LB, Zimmerman GA. The acute respiratory distress syndrome. J Clin Invest 2012, 122:2731-2740. 10.1172/JCI60331, 3408735, 22850883.
4. Shaykhiev R, Bals R. Interactions between epithelial cells and leukocytes in immunity and tissue homeostasis. J Leukoc Biol 2007, 82:1-15. 10.1189/jlb.0207096, 17452476.
5. Bals R, Weiner DJ, Wilson JM. The innate immune system in cystic fibrosis lung disease. J Clin Invest 1999, 103:303-307. 10.1172/JCI6277, 407907, 9927489.
6. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008, 359:2355-2365. 10.1056/NEJMra0800353, 19038881.
7. Dubin PJ, Martz A, Eisenstatt JR, Fox MD, Logar A, Kolls JK. Interleukin-23-mediated inflammation in Pseudomonas aeruginosa pulmonary infection. Infect Immun 2012, 80:398-409. 10.1128/IAI.05821-11, 3255685, 22025517.
8. Dalhoff A. Immunomodulatory activities of fluoroquinolones. Infection 2005, 33(Suppl 2):55-70.
9. Wilson R, Anzueto A, Miravitlles M, Arvis P, Alder J, Haverstock D, Trajanovic M, Sethi S. Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results. Eur Respir J 2012, 40:17-27. 10.1183/09031936.00090311, 3393767, 22135277.
10. Lister PD, Sanders CC. Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae. J Antimicrob Chemother 2001, 47:811-818. 10.1093/jac/47.6.811, 11389113.
11. Woodcock JM, Andrews JM, Boswell FJ, Brenwald NP, Wise R. In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob Agents Chemother 1997, 41:101-106. 163668, 8980763.
12. Zhang L, Li XZ, Poole K. Fluoroquinolone susceptibilities of efflux-mediated multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Burkholderia cepacia. J Antimicrob Chemother 2001, 48:549-552. 10.1093/jac/48.4.549, 11581236.
13. Buyck JM, Tulkens PM, Van BF. Pharmacodynamic evaluation of the intracellular activity of antibiotics towards Pseudomonas aeruginosa PAO1 in a model of THP-1 human monocytes. Antimicrob Agents Chemother 2013, 57:2310-2318. 10.1128/AAC.02609-12, 3632903, 23478951.
14. Araujo FG, Slifer TL, Remington JS. Effect of moxifloxacin on secretion of cytokines by human monocytes stimulated with lipopolysaccharide. Clin Microbiol Infect 2002, 8:26-30. 10.1046/j.1469-0691.2002.00374.x, 11906497.
15. Weiss T, Shalit I, Blau H, Werber S, Halperin D, Levitov A, Fabian I. Anti-inflammatory effects of moxifloxacin on activated human monocytic cells: inhibition of NF-kappaB and mitogen-activated protein kinase activation and of synthesis of proinflammatory cytokines. Antimicrob Agents Chemother 2004, 48:1974-1982. 10.1128/AAC.48.6.1974-1982.2004, 415605, 15155187.
16. Choi JH, Song MJ, Kim SH, Choi SM, Lee DG, Yoo JH, Shin WS. Effect of moxifloxacin on production of proinflammatory cytokines from human peripheral blood mononuclear cells. Antimicrob Agents Chemother 2003, 47:3704-3707. 10.1128/AAC.47.12.3704-3707.2003, 296188, 14638469.
17. Werber S, Shalit I, Fabian I, Steuer G, Weiss T, Blau H. Moxifloxacin inhibits cytokine-induced MAP kinase and NF-kappaB activation as well as nitric oxide synthesis in a human respiratory epithelial cell line. J Antimicrob Chemother 2005, 55:293-300. 10.1093/jac/dkh525, 15659543.
18. Blau H, Klein K, Shalit I, Halperin D, Fabian I. Moxifloxacin but not ciprofloxacin or azithromycin selectively inhibits IL-8, IL-6, ERK1/2, JNK, and NF-kappaB activation in a cystic fibrosis epithelial cell line. Am J Physiol Lung Cell Mol Physiol 2007, 292:L343-L352.
19. Dalhoff A, Shalit I. Immunomodulatory effects of quinolones. Lancet Infect Dis 2003, 3:359-371. 10.1016/S1473-3099(03)00658-3, 12781508.
20. Bailly S, Fay M, Roche Y, Gougerot-Pocidalo MA. Effects of quinolones on tumor necrosis factor production by human monocytes. Int J Immunopharmacol 1990, 12:31-36. 10.1016/0192-0561(90)90065-U, 1689279.
21. Riesbeck K, Forsgren A, Henriksson A, Bredberg A. Ciprofloxacin induces an immunomodulatory stress response in human T lymphocytes. Antimicrob Agents Chemother 1998, 42:1923-1930. 105711, 9687385.
22. Ratner AJ, Lysenko ES, Paul MN, Weiser JN. Synergistic proinflammatory responses induced by polymicrobial colonization of epithelial surfaces. Proc Natl Acad Sci U S A 2005, 102:3429-3434. 10.1073/pnas.0500599102, 552945, 15728393.
23. Beisswenger C, Kandler K, Hess C, Garn H, Felgentreff K, Wegmann M, Renz H, Vogelmeier C, Bals R. Allergic airway inflammation inhibits pulmonary antibacterial host defense. J Immunol 2006, 177:1833-1837. 10.4049/jimmunol.177.3.1833, 16849494.
24. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001, 29:e45. 10.1093/nar/29.9.e45, 55695, 11328886.
25. Hess C, Herr C, Beisswenger C, Zakharkina T, Schmid RM, Bals R. Myeloid RelA regulates pulmonary host defense networks. Eur Respir J 2010, 35:343-352. 10.1183/09031936.00196408, 19679599.
26. Ewig S, Hecker H, Suttorp N, Marre R, Welte T. Moxifloxacin monotherapy versus ss-lactam mono- or combination therapy in hospitalized patients with community-acquired pneumonia. J Infect 2011, 62:218-225. 10.1016/j.jinf.2011.01.009, 21276814.
27. Kazama I, Tamada T, Nakajima T. Resolution of migratory pulmonary infiltrates by moxifloxacin in a patient with dual infection of Mycoplasma pneumoniae and Bordetella pertussis. Infez Med 2012, 20:288-292.
28. Shalit I, Horev-Azaria L, Fabian I, Blau H, Kariv N, Shechtman I, Alteraz H, Kletter Y. Immunomodulatory and protective effects of moxifloxacin against Candida albicans-induced bronchopneumonia in mice injected with cyclophosphamide. Antimicrob Agents Chemother 2002, 46:2442-2449. 10.1128/AAC.46.8.2442-2449.2002, 127325, 12121916.
29. Pfeifer P, Voss M, Wonnenberg B, Hellberg J, Seiler F, Lepper PM, Bischoff M, Langer F, Schafers HJ, Menger MD, Bals R, Beisswenger C. IL-17C is a mediator of respiratory epithelial innate immune response. Am J Respir Cell Mol Biol 2013, 48:415-421. 10.1165/rcmb.2012-0232OC, 23221046.
30. Sander LE, Davis MJ, Boekschoten MV, Amsen D, Dascher CC, Ryffel B, Swanson JA, Muller M, Blander JM. Detection of prokaryotic mRNA signifies microbial viability and promotes immunity. Nature 2011, 474:385-389. 10.1038/nature10072, 3289942, 21602824.